本帖最后由 老马 于 2012-1-13 21:20 编辑 # _4 c9 N) F5 e: a/ r
5 R0 j+ m$ S. `6 U* n爱必妥和阿瓦斯丁的比较$ T, Z' U, c( u/ o9 N# y
+ g3 ~5 P: i" B) c& `
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
- _6 l# K! w; q8 x: U/ ^9 r% E
$ f+ Z8 ?5 f9 ^# t& g% D, t* U
) D, \9 R' m) ]7 H
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ ^2 r9 k$ C( z Z5 w; X( Q
==================================================
2 g0 t! X: O+ Y0 T8 [2 pOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): S$ f9 R# {: i5 S" R
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 c& W( |( @: H0 K# p, IResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ f' Q5 w- M, t- J, M' s, s
|
显身卡
